216 related articles for article (PubMed ID: 22177374)
1. Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men.
Yang G; Fu Z; Chen X; Yuan H; Yang H; Huang Y; Ouyang D; Tan Z; Tan H; Huang Z; Zhou H
Clin Ther; 2011 Dec; 33(12):2060-70. PubMed ID: 22177374
[TBL] [Abstract][Full Text] [Related]
2. Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.
Zhang JJ; Zhang H; Ding XL; Ma S; Miao LY
Eur J Clin Pharmacol; 2013 Apr; 69(4):807-12. PubMed ID: 23097010
[TBL] [Abstract][Full Text] [Related]
3. Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin.
Wei KK; Zhang LR
Clin Drug Investig; 2015 Sep; 35(9):583-91. PubMed ID: 26293521
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.
Kharasch ED; Walker A; Isoherranen N; Hoffer C; Sheffels P; Thummel K; Whittington D; Ensign D
Clin Pharmacol Ther; 2007 Oct; 82(4):410-26. PubMed ID: 17554244
[TBL] [Abstract][Full Text] [Related]
5. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
6. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.
Oneda B; Crettol S; Jaquenoud Sirot E; Bochud M; Ansermot N; Eap CB
Pharmacogenet Genomics; 2009 Nov; 19(11):877-83. PubMed ID: 19801957
[TBL] [Abstract][Full Text] [Related]
7. Effect of breviscapine on CYP3A metabolic activity in healthy volunteers.
Zhou X; Gao YY; Hu JY; Dong Y; Zhang HZ; Lai Y
Eur J Clin Pharmacol; 2018 Jan; 74(1):37-44. PubMed ID: 28986606
[TBL] [Abstract][Full Text] [Related]
8. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
[TBL] [Abstract][Full Text] [Related]
9. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin.
Elens L; Nieuweboer AJ; Clarke SJ; Charles KA; de Graan AJ; Haufroid V; van Gelder T; Mathijssen RH; van Schaik RH
Pharmacogenet Genomics; 2013 Mar; 23(3):148-55. PubMed ID: 23324807
[TBL] [Abstract][Full Text] [Related]
10. Effect of quercetin on CYP3A activity in Chinese healthy participants.
Duan KM; Wang SY; Ouyang W; Mao YM; Yang LJ
J Clin Pharmacol; 2012 Jun; 52(6):940-6. PubMed ID: 21680781
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP3A5*3 polymorphism and interaction between CYP3A5*3 and CYP3A4*1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery.
Zhang W; Yuan JJ; Kan QC; Zhang LR; Chang YZ; Wang ZY; Li ZS
Eur J Anaesthesiol; 2011 Apr; 28(4):245-50. PubMed ID: 21513075
[TBL] [Abstract][Full Text] [Related]
12. Effect of CYP3A4*1G, CYP3A5*3, POR*28, and ABCB1 C3435T on the pharmacokinetics of nifedipine in healthy Chinese volunteers.
Wang XF; Yan L; Cao HM; Wei LM; Yang WH; Zhang SJ; Zhang LR
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):737-45. PubMed ID: 26104034
[TBL] [Abstract][Full Text] [Related]
13. Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.
Chan SW; Xiao Y; Hu M; Yin OQ; Chu TT; Fok BS; Lee VH; Tomlinson B
J Clin Pharm Ther; 2016 Oct; 41(5):552-8. PubMed ID: 27511886
[TBL] [Abstract][Full Text] [Related]
14. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
[TBL] [Abstract][Full Text] [Related]
16. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
17. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients.
de Jonge H; Metalidis C; Naesens M; Lambrechts D; Kuypers DR
Pharmacogenomics; 2011 Sep; 12(9):1281-91. PubMed ID: 21770725
[TBL] [Abstract][Full Text] [Related]
18. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.
Yu KS; Cho JY; Jang IJ; Hong KS; Chung JY; Kim JR; Lim HS; Oh DS; Yi SY; Liu KH; Shin JG; Shin SG
Clin Pharmacol Ther; 2004 Aug; 76(2):104-12. PubMed ID: 15289787
[TBL] [Abstract][Full Text] [Related]
19. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
Li X; Junge L; Taubert M; von Georg A; Dahlinger D; Starke C; Frechen S; Stelzer C; Kinzig M; Sörgel F; Jaehde U; Töx U; Goeser T; Fuhr U
J Clin Pharmacol; 2020 Sep; 60(9):1237-1253. PubMed ID: 32427354
[TBL] [Abstract][Full Text] [Related]
20. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]